Successful Within-Patient Dose Escalation of Olipudase Alfa in Acid Sphingomyelinase Deficiency
Molecular Genetics and Metabolism 116 (2015) 88–97 Contents lists available at ScienceDirect Molecular Genetics and Metabolism journal homepage: www.elsevier.com/locate/ymgme Successful within-patient dose escalation of olipudase alfa in acid sphingomyelinase deficiency☆ Melissa P. Wasserstein a, Simon A. Jones b,HandreanSoranc,GeorgeA.Diaza, Natalie Lippa a,BethL.Thurbergd, Kerry Culm-Merdek e,EliasShamiyehe, Haig Inguilizian f,GeraldF.Coxg, Ana Cristina Puga g,⁎ a Genetics and Genomics Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA b Manchester Centre for Genomic Medicine, St. Mary's Hospital, CMFT, University of Manchester, Manchester, UK c Cardiovascular Trials Unit, Central Manchester University Hospital, Manchester, UK d Pathology, Genzyme, a Sanofi company, Cambridge, MA, USA e Clinical and Experimental Pharmacology, Sanofi, Bridgewater, NJ, USA f Global Safety, Genzyme, a Sanofi company, Cambridge, MA, USA g Clinical Development, Genzyme, a Sanofi company, Cambridge, MA, USA article info abstract Article history: Background: Olipudase alfa, a recombinant human acid sphingomyelinase (rhASM), is an investigational enzyme Received 14 April 2015 replacement therapy (ERT) for patients with ASM deficiency [ASMD; Niemann–Pick Disease (NPD) A and B]. This Received in revised form 27 May 2015 open-label phase 1b study assessed the safety and tolerability of olipudase alfa using within-patient dose escala- Accepted 27 May 2015 tion to gradually debulk accumulated sphingomyelin and mitigate the rapid production of metabolites, which Available online 30 May 2015 can be toxic. Secondary objectives were pharmacokinetics, pharmacodynamics, and exploratory efficacy. Methods: Five adults with nonneuronopathic ASMD (NPD B) received escalating doses (0.1 to 3.0 mg/kg) of Keywords: olipudase alfa intravenously every 2 weeks for 26 weeks.
[Show full text]